Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9935896 | 0.93 | PDK2 (0.44) | PDE3BPDE3AP2RY12PDK2MEN1 | |
| SCHEMBL9933210 | 0.84 | PLA2G2A (0.43) | PDE3BPDE3AP2RY12PDK2SMN1; SMN2 | |
| SCHEMBL9935492 | 0.83 | PDE3B (0.45) | PDE3BPDE3AP2RY12PDK2SMN1; SMN2 | |
| SCHEMBL28008191 | 0.82 | PDE3B (0.44) | PDE3BPDE3AP2RY12PDK2SMN1; SMN2 | |
| SCHEMBL9934767 | 0.80 | PDK2 (0.46) | PDE3BPDE3AP2RY12PDK2SMN1; SMN2 | |
| SCHEMBL10475104 | 0.79 | PDE3B (0.47) | PDE3BPDE3AP2RY12MAPT | |
| SCHEMBL9934966 | 0.78 | PDK2 (0.40) | PDE3BPDE3AP2RY12PDK2L3MBTL1 | |
| SCHEMBL9933532 | 0.77 | L3MBTL1 (0.57) | PDK2ALDH1A1LMNAL3MBTL1MAPK1 | |
| SCHEMBL9935226 | 0.77 | NR1I2 (0.37) | PDE3BPDE3AP2RY12PDK2ALDH1A1 | |
| SCHEMBL27647098 | 0.76 | PDIA6 (0.34) | SMN1; SMN2GAAL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9040525-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-8765752-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2703394-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| EP-2703393-A1 | CYCLIC AMIDE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| CN-103517898-A | Novel 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARM CO LTD | 2014-01-15 | — | — | CN | disclosed |
| US-8629102-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130210721-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-01 | — | — | US | disclosed |
| EP-2518060-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | PDE3B 1366/4885PDE3A 1637/4885P2RY12 111/4885 |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | PDE3B 1451/4885PDE3A 1749/4885P2RY12 149/4885 |
| US-20130210721-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | GPR119, GPR27, GPR65 | PDE3B 2125/4885PDE3A 2313/4885P2RY12 606/4885 |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | GPR119, GPR27, GPR65 | PDE3B 2125/4885PDE3A 2313/4885P2RY12 606/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | PDE3B 1428/4885PDE3A 2020/4885P2RY12 379/4885 |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | PDE3B 2073/4885PDE3A 2299/4885P2RY12 371/4885 |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | PDE3B 2033/4885PDE3A 2602/4885P2RY12 237/4885 |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | GPR119, GPR27, GPR65 | PDE3B 2053/4885PDE3A 2229/4885P2RY12 588/4885 |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | PDE3B 1425/4885PDE3A 2082/4885P2RY12 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.